Targeting NGF-pathway for developing neuroprotective therapies for multiple sclerosis and other neurological diseases

Archives Italiennes de Biologie

Volumn 149, Issue 2, 2011, Pages 183-192

  Colafrancesco, V ^a   Viloslada, P ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Multiple sclerosis; Nerve growth factor; Neuroinflammation; Neuroprotection

Indexed keywords

NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; DRUG DEVELOPMENT; HUMAN; METABOLISM; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE;

ANIMALS; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS; NERVE GROWTH FACTOR; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS;

EID: 79958110929     PISSN: 00039829     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Aktas O., Kieseier B., Hartung H.P. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci., 33: 140-152, 2009.
2. Aloyz R.S., Bamji S.X., Pozniak C.D., Toma J.G., Atwal J., Kaplan D.R., Miller F.D. p53 is essential for developmental neuron death as regulated by the TrkA and p75 neurotrophin receptors. J. Cell Biol., 143: 1691-703, 1998.
3. Arredondo L.R., Deng C., Ratts R.B., Lovett-Racke A.E., Holtzman D.M., Racke M.K. Role of nerve growth factor in experimental autoimmune encephalomyelitis. Eur. J. Immunol., 31: 625-633, 2001.
4. Awatsuji H., Furukawa Y., Hirota M., Furukawa S., Hayashi K. Interferons suppress nerve growth factor synthesis as a result of interference with cell growth in astrocytes cultured from neonatal mouse brain. J. Neurochem., 64: 1476-1482, 1995.
5. Awatsuji H., Furukawa Y., Hirota M., Murakami Y., Nii S., Furukawa S., Hayashi K. Interleukin-4 and -5 as modulators of nerve growth factor synthesis/ secretion in astrocytes. J. Neurosci. Res., 34: 539-545, 1993.
6. Barde Y.A., Edgar D., Thoenen H. New neurotrophic factors. Annu. Rev. Physiol., 45: 601-612, 1983.
7. Becher B., Bechmann I., Greter M. Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain. J. Mol. Med., 84: 532-543, 2006.
8. Blesch A. Neurotrophin gene therapy for Alzheimer's disease. Future Neurol., 1: 179-187, 2006.
9. Boutros T., Croze E., Yong V.W. Interferon-beta is a potent promoter of nerve growth factor production by astrocytes. J. Neurochem., 69: 939-946, 1997.
10. Bradl M. and Linington C. Animal models of demyelination. Brain Pathol., 6: 303-311, 1996.
11. Brodie C. Differential effects of Th1 and Th2 derived cytokines on NGF synthesis by mouse astrocytes. FEBS Lett., 394: 117-120, 1996.
12. Calza L., Giardino L., Pozza M., Bettelli C., Micera A., Aloe L. Proliferation and phenotype regulation in the subventricular zone during experimental allergic encephalomyelitis: in vivo evidence of a role for nerve growth factor. Proc. Natl. Acad. Sci. U.S.A., 95: 3209-3214, 1998.
13. Casaccia-Bonnefil P., Gu C., Chao M.V. Neurotrophins in cell survival/death decisions. Adv. Exp. Med. Biol., 468: 275-282, 1999.
14. Conner J.M., Franks K.M., Titterness A.K., Russell K., Merrill D.A., Christie B.R., Sejnowski T.J., Tuszynski M.H. NGF is essential for hippocampal plasticity and learning. J. Neurosci., 29: 10883-10889, 2009.
15. Connor B. and Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res. Rev., 27: 1-39, 1998.
16. Cowan W.M., Hamburger V., Levi-Montalcini R. The path to the discovery of nerve growth factor. Annu. Rev. Neurosci., 24: 551-600, 2001.
17. De Simone R., Micera A., Tirassa P., Aloe L. mRNA for NGF and p75 in the central nervous system of rats affected by experimental allergic encephalomyelitis. Neuropathol. Appl. Neurobiol., 22: 54-59, 1996.
18. Di Monte D.A., Schipper H.M., Hetts S., Langston J.W. Iron-mediated bioactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in glial cultures. Glia, 15: 203-206, 1995.
19. Drukarch B., van Muiswinkel F.L. Neuroprotection for Parkinson's disease: a new approach for a new millennium. Expert Opin. Investig. Drugs, 10: 1855-1868, 2001.
20. Ehrhard P.B., Erb P., Graumann U., Otten U. Expression of nerve growth factor and nerve growth factor receptor tyrosine kinase Trk in activated CD4-positive T-cell clones. Proc. Natl. Acad. Sci. U.S.A., 90: 10984-10988, 1993.
21. Elkabes S., DiCicco-Bloom E.M., Black I.B. Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function. J. Neurosci., 16: 2508-2521, 1996.
22. Elmariah S.B., Hughes E.G., Oh E.J., Balice-Gordon R.J. Neurotrophin signaling among neurons and glia during formation of tripartite synapses. Neuron. Glia Biol., 1: 1-11, 2005.
23. Flugel A., Matsumuro K., Neumann H., Klinkert W.E., Birnbacher R., Lassmann H., Otten U., Wekerle H. Anti-inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration. Eur. J. Immunol., 31: 11-22, 2001.
24. Friedman W.J., Black I.B., Persson H., Ibanez C.F. Synergistic trophic actions on rat basal forebrain neurons revealed by a synthetic NGF/BDNF chimaeric molecule. Eur. J. Neurosci., 7: 656-662, 1995.
25. Gadient R.A., Cron K.C., Otten U. Interleukin-1 beta and tumor necrosis factor-alpha synergistically stimulate nerve growth factor (NGF) release from cultured rat astrocytes. Neurosci. Lett., 117: 335-340, 1990.
26. Hefti F. Neurotrophic factor therapy for nervous system degenerative diseases. J. Neurobiol., 25: 1418-1435, 1994.
27. Hickey W.F. Basic principles of immunological surveillance of the normal central nervous system. Glia, 36: 118-124, 2001.
28. Hickey W.F., Hsu B.L., Kimura H. T-lymphocyte entry into the central nervous system. J. Neurosci. Res., 28: 254-260, 1991.
29. Jang SW, Okada M, Sayeed I, Xiao G, Stein D, Jin P, Ye K. Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death. Proc Natl Acad Sci U.S.A., 104: 16329-16334, 2007.
30. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol., 53: S26-36, 2003.
31. Kafitz K.W., Rose C.R., Thoenen H., Konnerth A. Neurotrophin-evoked rapid excitation through TrkB receptors. Nature, 401: 918-921, 1999.
32. Kerschensteiner M., Gallmeier E., Behrens L., Leal V.V., Misgeld T., Klinkert W.E., Kolbeck R., Hoppe E., Oropeza-Wekerle R.L., Bartke I., Stadelmann C., Lassmann H., Wekerle H., Hohlfeld R. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J. Exp. Med., 189: 865-870, 1999.
33. Kim S.U. and De Vellis J. Stem cell-based cell therapy in neurological diseases: a review. J. Neuro. Res., 87: 2183-2200, 2009.
34. Kleine T.O. and Benes L. Immune surveillance of the human central nervous system (CNS): different migration pathways of immune cells through the blood-brain barrier and blood-cerebrospinal fluid barrier in healthy persons. Cytometry A., 69: 147-151, 2006.
35. Kramer R., Zhang Y., Gehrmann J., Gold R., Thoenen H., Wekerle H. Gene transfer through the bloodnerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis. Nat. Med., 1: 1162-1166, 1995.
36. Lambiase A, Aloe L, Centofanti M, Parisi V, Mantelli F, Colafrancesco V, Manni GL, Bucci MG, Bonini S, Levi-Montalcini R. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma. Proc. Natl. Acad. Sci. U.S.A., 106: 13469-13474, 2009.
37. Laske C., Stransky E., Leyhe T., Eschweiler G.W., Wittorf A., Richartz E., Bartels M., Buchkremer G., Schott K. Stage-dependent BDNF serum concentrations in Alzheimer's disease. J. Neural. Transm. 113: 1217-1224, 2006.
38. Laudiero L.B., Aloe L., Levi-Montalcini R., Buttinelli C., Schilter D., Gillessen S., Otten U. Multiple sclerosis patients express increased levels of beta-nerve growth factor in cerebrospinal fluid. Neurosci. Lett., 147: 9-12, 1992.
39. Leon A., Buriani A., Dal Toso R., Fabris M., Romanello S., Aloe L., Levi-Montalcini R. Mast cells synthesize, store, and release nerve growth factor. Proc. Natl. Acad. Sci. U.S.A., 91: 3739-3743, 1994.
40. Lindvall O., Kokaia Z., Bengzon J., Elmer E., Kokaia M. Neurotrophins and brain insults. Trends Neurosci., 17: 490-496, 1994.
41. Lykissas M.G., Batistatou A.K., Charalabopoulos K.A., Beris A.E. The role of neurotrophins in axonal growth, guidance, and regeneration. Curr. Neurovasc. Res., 4: 143-151, 2007.
42. McAllister A.K. Cellular and molecular mechanisms of dendrite growth. Cereb. Cortex., 10: 963-973, 2000.
43. McGeer E.G., Yasojima K., Schwab C., McGeer P.L. The pentraxins: possible role in Alzheimer's disease and other innate inflammatory diseases. Neurobiol. Aging., 22: 843-848, 2001.
44. Meakin S.O. and Shooter E.M. The nerve growth factor family of receptors. Trends Neurosci., 15: 323-331, 1992.
45. Micera A., Lambiase A., Rama P., Aloe L. Altered nerve growth factor level in the optic nerve of patients affected by multiple sclerosis. Mult. Scler., 5: 389-394, 1999.
46. Moalem G., Gdalyahu A., Shani Y., Otten U., Lazarovici P., Cohen I.R., Schwartz M. Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. J. Autoimmun., 15: 331-345, 2000.
47. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., Ichinose H., Nagatsu T. Brainderived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci. Lett., 270: 45-48, 1999.
48. Muhallab S., Lundberg C., Gielen A.W., Lidman O., Svenningsson A., Piehl F., Olsson T. Differential expression of neurotrophic factors and inflammatory cytokines by myelin basic protein-specific and other recruited T cells infiltrating the central nervous system during experimental autoimmune encephalomyelitis. Scand. J. Immunol., 55: 264-273, 2002.
49. Neumann H., Misgeld T., Matsumuro K., Wekerle H. Neurotrophins inhibit major histocompatibility class II inducibility of microglia: involvement of the p75 neurotrophin receptor. Proc. Natl. Acad. Sci. U.S.A., 95: 5779-5784, 1998.
50. Oderfeld-Nowak B., Zaremba M., Micera A., Aloe L. The upregulation of nerve growth factor receptors in reactive astrocytes of rat spinal cord during experimental autoimmune encephalomyelitis. Neurosci. Lett., 308: 165-168, 2001.
51. Ohira K. and Hayashi M. A New aspect of the TrkB signaling pathway in neural plasticity. Curr. Neuropharmacol., 7: 276-285, 2009.
52. Olanow C.W., Schapira A.H., Agid Y. Neuroprotection for Parkinson's disease: prospects and promises. Ann. Neurol., 53: S1-2, 2003.
53. Orr H.T. and Zoghbi H.Y. Reversing neurodegeneration: a promise unfolds. Cell, 101: 1-4, 2000.
54. Perry V.H. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav. Immun. 18: 407-413, 2004.
55. Persson H. and Ibanez C.F. Role and expression of neurotrophins and the trk family of tyrosine kinase receptors in neural growth and rescue after injury. Curr. Opin. Neurol. Neurosurg., 6: 11-18, 1993.
56. Petty B.G., Cornblath D.R., Adornato B.T., Chaudhry V., Flexner C., Wachsman M., Sinicropi D., Burton L.E., Peroutka S.J. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann. Neurol., 36: 244-246, 1994.
57. Phillips H.S., Hains J.M., Armanini M., Laramee G.R., Johnson S.A., Winslow J.W. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron., 7: 695-702, 1991.
58. Pradines A., Magazin M., Schiltz P., Le Fur G., Caput D., Ferrara P. Evidence for nerve growth factorpotentiating activities of the nonpeptidic compound SR 57746A in PC12 cells. J. Neurochem., 64: 1954-1964, 1995.
59. Price R.D., Milne S.A., Sharkey J., Matsuoka N. Advances in small molecules promoting neurotrophic function. Pharmacol. Ther., 115: 292-306, 2007.
60. Riccio A., Ahn S., Davenport C.M., Blendy J.A., Ginty D.D. Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons. Science., 286: 2358-2561, 1999.
61. Santambrogio L., Benedetti M., Chao M.V., Muzaffar R., Kulig K., Gabellini N., Hochwald G. Nerve growth factor production by lymphocytes. J. Immunol., 153: 4488-4495, 1994.
62. Saragovi H.U. and Burgess K., Small molecules and protein-baced neurotrophic ligands agonists and antagonists as therapeutic agents. Expert. Opin. Ther. Pat., 9: 737-751, 1999.
63. Saragovi H.U. and Gehring K. Development of pharmacological agents for targeting neurotrophins and their receptors. Trends Pharmacol. Sci., 21: 93-98, 2000.
64. Sherman M.Y., Goldberg A.L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron., 29: 15-32, 2001.
65. Song X.Y., Zhang F.H., Zhou F.H., Zhong J., Zhou X.F. Deletion of p75NTR impairs regeneration of peripheral nerves in mice. Life Sci., 84: 61-68, 2009.
66. Soontornniyomkij V., Wang G., Pittman C.A., Wiley C.A., Achim C.L. Expression of brain-derived neurotrophic factor protein in activated microglia of human immunodeficiency virus type 1 encephalitis. Neuropathol. Appl. Neurobiol., 24: 453-460, 1998.
67. Stadelmann C., Kerschensteiner M., Misgeld T., Bruck W., Hohlfeld R., Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain, 125: 75-85, 2002.
68. Thoenen H. The changing scene of neurotrophic factors. Trends Neurosci., 14: 165-170, 1991.
69. Torcia M., Bracci-Laudiero L., Lucibello M., Nencioni L., Labardi D., Rubartelli A., Cozzolino F., Aloe L., Garaci E. Nerve growth factor is an autocrine survival factor for memory B lymphocytes. Cell, 85: 345-356, 1996.
70. Tuszynski M.H. and Gage F.H. Maintaining the neuronal phenotype after injury in the adult CNS. Neurotrophic factors, axonal growth substrates, and gene therapy. Mol. Neurobiol., 10: 151-167, 1995.
71. Tuszynski M.H. New strategies for CNS repair. Ernst. Schering Res. Found Workshop, 53: 1-10, 2005.
72. Villoslada P. and Genain C.P. Role of nerve growth factor and other trophic factors in brain inflammation. Prog. Brain Res., 146: 403-414, 2004.
73. Villoslada P., Hauser S.L., Bartke I., Unger J., Heald N., Rosenberg D., Cheung S.W., Mobley W.C., Fisher S., Genain C.P. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J. Exp. Med., 191: 1799-1806, 2000.
74. Walker L.C. and LeVine H. The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly. Mol. Neurobiol., 21: 83-95, 2000.
75. Wei R., Jonakait G.M. Neurotrophins and the antiinflammatory agents interleukin-4 (IL-4), IL-10, IL-11 and transforming growth factor-beta1 (TGFbeta1) down-regulate T cell costimulatory molecules B7 and CD40 on cultured rat microglia. J. Neuroimmunol., 95: 8-18, 1999.
76. Wyss-Coray T. and Mucke L. Inflammation in neurodegenerative disease - a double-edged sword. Neuron., 35: 419-432, 2002.
77. Zhang Y., Moheban D.B., Conway B.R., Bhattacharyya A., Segal R.A. Cell surface Trk receptors mediate NGF-induced survival while internalized receptors regulate NGF-induced differentiation. J. Neurosci., 20: 5671-5678, 2000.